Piramal Healthcare invests $2.5 million to further expand commercial ADC capacity
By
Piramal’s healthcare vertical has announced that it is to invest $2.5 million at its FDA-approved site in Grangemouth, UK, to upgrade one of its antibody drug conjugate (ADC) manufacturing suites from clinical phase to commercial grade in response to customer demand.